^
Association details:
| Biomarker: | CCNE1 overexpression + PIK3CA muattion + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + taselisib (GDC-0032) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.
Published date:
09/21/2020
Excerpt:
The triplet therapy response rate in PIK3CA mutant, ER-positive HER2-negative was 37.5% (95% CI 18.8-59.4). In the triplet group, high baseline cyclin E1 expression associated with shorter progression-free survival (PFS) (HR 4.2, 95% CI 1.3-13.1, p=0.02).
Secondary therapy:
fulvestrant
DOI:
10.1158/2159-8290.CD-20-0553
